Liquidia Corporation is scheduled to report second-quarter results on August 12, with the Zacks Consensus Estimate for sales at $165.25 million and earnings per share at 70 cents. The company has a strong earnings surprise history, beating estimates in three of the last four quarters by an average of 54.4%, though its Earnings ESP for the upcoming report is 0.00% despite a Zacks Rank of 1. Yutrepia, its inhaled dry-powder treprostinil therapy approved in May 2025 and launched in June 2025, has driven rapid growth, surpassing a $500 million annualized revenue run rate within its first year and recording more than 4,500 unique prescriptions, around 3,750 patient starts, and nearly 980 prescribing physicians. Liquidia also generates revenue through a profit-sharing agreement with Sandoz for generic treprostinil injection and is advancing L606, an extended-release treprostinil formulation, in clinical trials. Shares have surged 151.7% year to date, and management remains confident in achieving at least $1 billion in annual revenues by 2027, funded entirely through operating cash flow.
Liquidia Technologies IncYutrepia's rapid growth with strong prescription and revenue run rate
United Therapeutics CorporationLiquidia's Yutrepia competes with United Therapeutics' treprostinil products
Johnson & Johnson
Sandoz Group AG